Liposyn reports top-line safety and efficacy results for LPCN 1154 in patients with postpartum depression
In a phase 3 study population of patients with PPD (N = 90), LPCN 1154 did not demonstrate a statistically significant reduction from baseline in the HAM-D17 total score at 60 hours (primary endpoint) compared to placebo. The primary endpoint was not met In a post hoc analysis of participants (n = 54) with a … Read more